Cargando…
Systemic Sclerosis Is Linked to Psoriasis and May Impact on Patients’ Survival: A Large Cohort Study
Although skin manifestations are quite common in systemic sclerosis (SSc), a link between SSc and psoriasis (PsO) has been poorly investigated. We assessed the Clalit medical database in a cohort study to compare the prevalence of PsO between SSc-patients and SSc-free controls. We also evaluated the...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6517892/ https://www.ncbi.nlm.nih.gov/pubmed/30995800 http://dx.doi.org/10.3390/jcm8040521 |
_version_ | 1783418346051469312 |
---|---|
author | Watad, Abdulla Bragazzi, Nicola Luigi McGonagle, Dennis Damiani, Giovanni Comaneshter, Doron Cohen, Arnon Amital, Howard |
author_facet | Watad, Abdulla Bragazzi, Nicola Luigi McGonagle, Dennis Damiani, Giovanni Comaneshter, Doron Cohen, Arnon Amital, Howard |
author_sort | Watad, Abdulla |
collection | PubMed |
description | Although skin manifestations are quite common in systemic sclerosis (SSc), a link between SSc and psoriasis (PsO) has been poorly investigated. We assessed the Clalit medical database in a cohort study to compare the prevalence of PsO between SSc-patients and SSc-free controls. We also evaluated the SSc-related autoantibodies’ role in the co-existence of the two conditions. Survival analysis was performed using both univariate (Kaplan–Meier, log-rank test) and multivariate (Cox proportional-hazards technique) analyses. Our cohort of 2,431 SSc-patients was age- and gender-matched with 12,710 controls (case-control match 1:5.2). There were 150 (1.2%) cases of PsO among controls and 47 (1.9%) among SSc-patients (p = 0.0027). A SSc diagnosis was an independent risk factor for PsO with an odds ratio (OR) of 2.16 (95%CI 1.38–3.39, p = 0.0008). Among SSc-patients, 98.6% with PsO were antinuclear antibodies (ANA)-negative. In terms of survival, the mortality rate in SSc-patients with PsO was lower than SSc without PsO (14.9% vs. 26%, p < 0.0001). At the multivariate-analysis, SSc-patients with PsO compared to SSc-patients without PsO had an OR for death of 0.44 (95%CI 0.19–0.99, p < 0.05). SSc is independently associated with PsO. The cases with concurrent PsO and SSc are almost exclusively ANA-negative and may exhibit a better survival. |
format | Online Article Text |
id | pubmed-6517892 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-65178922019-05-31 Systemic Sclerosis Is Linked to Psoriasis and May Impact on Patients’ Survival: A Large Cohort Study Watad, Abdulla Bragazzi, Nicola Luigi McGonagle, Dennis Damiani, Giovanni Comaneshter, Doron Cohen, Arnon Amital, Howard J Clin Med Article Although skin manifestations are quite common in systemic sclerosis (SSc), a link between SSc and psoriasis (PsO) has been poorly investigated. We assessed the Clalit medical database in a cohort study to compare the prevalence of PsO between SSc-patients and SSc-free controls. We also evaluated the SSc-related autoantibodies’ role in the co-existence of the two conditions. Survival analysis was performed using both univariate (Kaplan–Meier, log-rank test) and multivariate (Cox proportional-hazards technique) analyses. Our cohort of 2,431 SSc-patients was age- and gender-matched with 12,710 controls (case-control match 1:5.2). There were 150 (1.2%) cases of PsO among controls and 47 (1.9%) among SSc-patients (p = 0.0027). A SSc diagnosis was an independent risk factor for PsO with an odds ratio (OR) of 2.16 (95%CI 1.38–3.39, p = 0.0008). Among SSc-patients, 98.6% with PsO were antinuclear antibodies (ANA)-negative. In terms of survival, the mortality rate in SSc-patients with PsO was lower than SSc without PsO (14.9% vs. 26%, p < 0.0001). At the multivariate-analysis, SSc-patients with PsO compared to SSc-patients without PsO had an OR for death of 0.44 (95%CI 0.19–0.99, p < 0.05). SSc is independently associated with PsO. The cases with concurrent PsO and SSc are almost exclusively ANA-negative and may exhibit a better survival. MDPI 2019-04-16 /pmc/articles/PMC6517892/ /pubmed/30995800 http://dx.doi.org/10.3390/jcm8040521 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Watad, Abdulla Bragazzi, Nicola Luigi McGonagle, Dennis Damiani, Giovanni Comaneshter, Doron Cohen, Arnon Amital, Howard Systemic Sclerosis Is Linked to Psoriasis and May Impact on Patients’ Survival: A Large Cohort Study |
title | Systemic Sclerosis Is Linked to Psoriasis and May Impact on Patients’ Survival: A Large Cohort Study |
title_full | Systemic Sclerosis Is Linked to Psoriasis and May Impact on Patients’ Survival: A Large Cohort Study |
title_fullStr | Systemic Sclerosis Is Linked to Psoriasis and May Impact on Patients’ Survival: A Large Cohort Study |
title_full_unstemmed | Systemic Sclerosis Is Linked to Psoriasis and May Impact on Patients’ Survival: A Large Cohort Study |
title_short | Systemic Sclerosis Is Linked to Psoriasis and May Impact on Patients’ Survival: A Large Cohort Study |
title_sort | systemic sclerosis is linked to psoriasis and may impact on patients’ survival: a large cohort study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6517892/ https://www.ncbi.nlm.nih.gov/pubmed/30995800 http://dx.doi.org/10.3390/jcm8040521 |
work_keys_str_mv | AT watadabdulla systemicsclerosisislinkedtopsoriasisandmayimpactonpatientssurvivalalargecohortstudy AT bragazzinicolaluigi systemicsclerosisislinkedtopsoriasisandmayimpactonpatientssurvivalalargecohortstudy AT mcgonagledennis systemicsclerosisislinkedtopsoriasisandmayimpactonpatientssurvivalalargecohortstudy AT damianigiovanni systemicsclerosisislinkedtopsoriasisandmayimpactonpatientssurvivalalargecohortstudy AT comaneshterdoron systemicsclerosisislinkedtopsoriasisandmayimpactonpatientssurvivalalargecohortstudy AT cohenarnon systemicsclerosisislinkedtopsoriasisandmayimpactonpatientssurvivalalargecohortstudy AT amitalhoward systemicsclerosisislinkedtopsoriasisandmayimpactonpatientssurvivalalargecohortstudy |